RxDoctor Payments DataLook up a doctor →

George Therapondos, MD

Hepatology · New Orleans, LANPI 1093099715

Payments from drug & device makers

$925,248in general payments, 2019–2025

Across 434 payments — averaging $2131.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intercept Pharmaceuticals, Inc.$244K
  • Madrigal Pharmaceuticals$188K
  • Novo Nordisk$107K
  • E.r. Squibb & Sons, L.L.C.$102K
  • Bristol Myers Squibb$68K
  • Gilead$45K
  • plus $171K from 12 others

What the payments were for

  • Consulting fees$114,34631%
  • Speaking & faculty fees$209,56557%
  • Travel & lodging$30,1528%
  • Food & beverage$10,3293%
  • Education$1160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$31,486
Medicare patients
162
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin41$134,588
Tacrolimus607$52,582
VemlidyTenofovir Alafenamide23$31,339
DescovyEmtricitabine/Tenofov Alafenam13$25,320
Ursodiol153$17,394
Lamivudine147$9,921
XareltoRivaroxaban12$6,346
Mycophenolic AcidMycophenolate Sodium17$5,667
Sirolimus15$5,248
Mycophenolate Mofetil76$3,129
Tenofovir Disoproxil Fumarate48$1,827
Entecavir46$1,471
Azathioprine51$688
Spironolactone71$675
Lactulose35$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy, Descovy$44,702$56,65936 claims
Johnson & JohnsonXarelto$4,754$6,34612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other hepatology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →